Literature DB >> 33235330

Spectrum and impact of checkpoint inhibitor-induced irAEs.

Laura C Cappelli1, Clifton O Bingham2.   

Abstract

Mesh：

Substances：

Year:  2021        PMID： 33235330     DOI： 10.1038/s41584-020-00546-2

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  3 in total

1.  Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.

Authors:  Amy Cunningham-Bussel; Jiaqi Wang; Lauren C Prisco; Lily W Martin; Kathleen M M Vanni; Alessandra Zaccardelli; Mazen Nasrallah; Lydia Gedmintas; Lindsey A MacFarlane; Nancy A Shadick; Mark M Awad; Osama Rahma; Nicole R LeBoeuf; Ellen M Gravallese; Jeffrey A Sparks
Journal:  Arthritis Rheumatol       Date:  2022-01-25       Impact factor: 10.995

Review 2.  Immune-checkpoint inhibitors: long-term implications of toxicity.

Authors:  Douglas B Johnson; Caroline A Nebhan; Javid J Moslehi; Justin M Balko
Journal:  Nat Rev Clin Oncol       Date:  2022-01-26       Impact factor: 65.011

Review 3.  Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.

Authors:  Remo Poto; Teresa Troiani; Gjada Criscuolo; Giancarlo Marone; Fortunato Ciardiello; Carlo Gabriele Tocchetti; Gilda Varricchi
Journal:  Front Immunol       Date:  2022-03-30       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.